ketoconazole has been researched along with Dermatitis Seborrheica in 95 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double masked, placebo controlled clinical trial, of topical 2% ketoconazole cream with lid hygiene, for the treatment of seborrhoeic and mixed seborrhoeic/staphylococcal blepharitis was conducted." | 9.06 | Ketoconazole in the treatment of blepharitis. ( Blatchford, NR; Midgley, G; Nelson, ME, 1990) |
| "The role of Malassezia yeasts in dandruff and seborrheic dermatitis is unclear; however, antifungal therapy with ketoconazole is commonly used." | 8.12 | Ketoconazole beyond antifungal activity: Bioinformatics-based hypothesis on lipid metabolism in dandruff and seborrheic dermatitis. ( Goularte-Silva, V; Paulino, LC, 2022) |
| "Ketoconazole is a widely used imidazole antifungal agent." | 5.40 | Allergic contact dermatitis from ketoconazole. ( Liu, J; Warshaw, EM, 2014) |
| "A double masked, placebo controlled clinical trial, of topical 2% ketoconazole cream with lid hygiene, for the treatment of seborrhoeic and mixed seborrhoeic/staphylococcal blepharitis was conducted." | 5.06 | Ketoconazole in the treatment of blepharitis. ( Blatchford, NR; Midgley, G; Nelson, ME, 1990) |
| "The role of Malassezia yeasts in dandruff and seborrheic dermatitis is unclear; however, antifungal therapy with ketoconazole is commonly used." | 4.12 | Ketoconazole beyond antifungal activity: Bioinformatics-based hypothesis on lipid metabolism in dandruff and seborrheic dermatitis. ( Goularte-Silva, V; Paulino, LC, 2022) |
| "Selenium disulfide provides an additional benefit on the scalp microbiota and in clinical symptoms of SD and dandruff after treatment with ketoconazole." | 4.12 | Continuous clinical improvement of mild-to-moderate seborrheic dermatitis and rebalancing of the scalp microbiome using a selenium disulfide-based shampoo after an initial treatment with ketoconazole. ( Bouloc, A; Clavaud, C; Guéniche, A; Kerob, D; Massiot, P; Michelin, C; Muller, B; Ott, A; Panhard, S; Reygagne, P; Thomas, M, 2022) |
| "Facial seborrheic dermatitis (SD) is an inflammatory skin disease characterized by erythematous and scaly lesions on the skin with high sebaceous gland activity." | 3.30 | Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial. ( Bouwstra, JA; Burggraaf, J; de Kam, ML; Feiss, GL; Gambrah, T; Haakman, J; Nădăban, A; Niemeyer-van der Kolk, T; Pagan, L; Rissmann, R; Rousel, J; Saghari, M; Theelen, B; van der Wall, HEC; van Doorn, MBA, 2023) |
| "Miconazole shampoo is at least as effective and safe as ketoconazole shampoo in treating scalp seborrheic dermatitis scalp." | 2.79 | Multicenter, double-blind, parallel group study investigating the non-inferiority of efficacy and safety of a 2% miconazole nitrate shampoo in comparison with a 2% ketoconazole shampoo in the treatment of seborrhoeic dermatitis of the scalp. ( Buechner, SA, 2014) |
| " Subjects were evaluated at baseline and at weeks 4, 8, 16, 26, 39, and 52 (or early termination [ET]) for adverse events (AEs), serious AEs (SAEs), target lesion erythema, scaling, and pruritus, as well as Investigator's Static Global Assessment (ISGA) scores." | 2.78 | Long-term safety of ketoconazole foam, 2% in the treatment of seborrheic dermatitis: results of a phase IV, open-label study. ( Alió Saenz, AB; Butners, V; Draelos, ZD; Feldman, SR, 2013) |
| " The short-contact clobetasol propionate 0·05% shampoo (CP) is an efficacious and safe once-daily treatment for scalp psoriasis." | 2.76 | Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0·05% combined with ketoconazole shampoo 2%: a randomized, controlled study. ( Faergemann, J; Kerrouche, N; Lee, JH; Nikkels, AF; Ortonne, JP; Ponce Olivera, RM; Reich, K; Sidou, F, 2011) |
| "Ciclopirox olamine (CPO) is a broad-spectrum antifungal with anti-inflammatory properties effective against the yeast implicated in seborrhoeic dermatitis, Malassezia spp." | 2.73 | Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis. ( Boorman, GC; Ratnavel, RC; Squire, RA, 2007) |
| "Ketoconazole foam 2% is a safe, effective, and versatile formulation for use on the scalp, body, and face for the treatment of seborrheic dermatitis in patients aged 12 years or older." | 2.73 | A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions. ( Abraham, S; Abramovits, W; Elewski, BE; Gupta, AK; Kempers, S; Rosen, T; Rowell, R; Schlessinger, J, 2007) |
| "Salicylic acid has keratolytic properties and aids in the removal of scales." | 2.70 | A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis ( Goode, K; Squire, RA, 2002) |
| "The pathobiology of seborrheic dermatitis is rooted in a peculiar inflammatory reaction to Malassezia spp." | 2.70 | A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis. ( Piérard, GE; Piérard-Franchimont, C, 2002) |
| "Ketoconazole is an antimycotic agent with a high in vitro and in vivo efficacy against P." | 2.68 | Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. ( Peter, RU; Richarz-Barthauer, U, 1995) |
| "Ketoconazole was statistically superior to selenium sulfide at day 8 only (p = 0." | 2.67 | A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. ( Danby, FW; Maddin, WS; Margesson, LJ; Rosenthal, D, 1993) |
| "Ketoconazole was also superior to betamethasone with reference to the evolution of the symptoms, irrespective of their localization." | 2.67 | Comparative study of ketoconazole 2% foaming gel and betamethasone dipropionate 0.05% lotion in the treatment of seborrhoeic dermatitis in adults. ( Lacour, JP; Le Fichoux, Y; Ortonne, JP; Vitetta, A, 1992) |
| "Fifty patients (42 men, 8 women) with seborrheic dermatitis were included in the trial." | 2.67 | Ketoconazole 2% emulsion in the treatment of seborrheic dermatitis. ( Hoppenbrouwers, ML; Piérard, GE; Piérard-Franchimont, C; Rurangirwa, A; Schrooten, P; Van Cutsem, J, 1991) |
| "Seventy-two patients with seborrheic dermatitis were treated once daily with 2% ketoconazole cream (n = 36) or 1% hydrocortisone cream (n = 36) on a double-blind basis for 4 weeks." | 2.66 | Ketoconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis. A double-blind comparative study. ( Antoniou, C; Böhler, K; De Beule, K; Fritsch, P; Katsambas, A; Michaelidis, D; Schmölz, A; Stratigos, JD, 1988) |
| "Thirty-seven patients with seborrheic dermatitis were treated topically with a 2% ketoconazole cream or its vehicle control in a double-blind study." | 2.66 | Double-blind treatment of seborrheic dermatitis with 2% ketoconazole cream. ( Guin, JD; Noah, PW; Rosenberg, EW; Skinner, RB; Taylor, RM; West, S; Zanolli, MD, 1985) |
| "Facial seborrheic dermatitis (SD), a chronic inflammatory skin condition, can impact quality of life, and relapses can be frequent." | 2.55 | Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review. ( Gupta, AK; Versteeg, SG, 2017) |
| "Pityriasis versicolor is the probably most frequent infection caused by Malassezia." | 2.52 | [Cutaneous Malassezia infections and Malassezia associated dermatoses: An update]. ( Krüger, C; Mayser, P; Nenoff, P, 2015) |
| "Ketoconazole gel 2% has been developed for the once-daily treatment of seborrheic dermatitis." | 2.44 | Ketoconazole gel 2% in the treatment of moderate to severe seborrheic dermatitis. ( Blockhuys, S; Decroix, J; Langner, A; Quiring, JN; Swinyer, LJ, 2007) |
| "Ketoconazole is a common antifungal used for the treatment of broad-spectrum mycoses, including Candida spp." | 2.42 | Ketoconazole foam--connetics: connetics ketoconazole foam. ( , 2003) |
| "Ketoconazole shampoo has been shown to suppress effectively both the organism's growth and the symptoms and signs of the clinical disorder." | 2.38 | An overview of experience with ketoconazole shampoo. ( Ive, FA, 1991) |
| "Ketoconazole treatment reduced Malassezia and increased fungal diversity to restore skin microbial communities." | 1.72 | Ketoconazole 2% cream alters the skin fungal microbiome in seborrhoeic dermatitis: a cohort study. ( Li, R; Song, Y; Tao, R; Wan, Z; Wang, R; Wu, Y, 2022) |
| "Ketoconazole is a widely used imidazole antifungal agent." | 1.40 | Allergic contact dermatitis from ketoconazole. ( Liu, J; Warshaw, EM, 2014) |
| "It constitutes a new alternative in the treatment of facial seborrheic dermatitis, regardless of severity." | 1.34 | [Lithium gluconate 8% in the treatment of seborrheic dermatitis]. ( Blouin, E; Dréno, B; Moyse, D, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (17.89) | 18.7374 |
| 1990's | 25 (26.32) | 18.2507 |
| 2000's | 35 (36.84) | 29.6817 |
| 2010's | 12 (12.63) | 24.3611 |
| 2020's | 6 (6.32) | 2.80 |
| Authors | Studies |
|---|---|
| Goularte-Silva, V | 1 |
| Paulino, LC | 2 |
| Tao, R | 1 |
| Wang, R | 1 |
| Wan, Z | 1 |
| Song, Y | 1 |
| Wu, Y | 2 |
| Li, R | 1 |
| Rousel, J | 1 |
| Saghari, M | 1 |
| Pagan, L | 1 |
| Nădăban, A | 1 |
| Gambrah, T | 1 |
| Theelen, B | 1 |
| de Kam, ML | 1 |
| Haakman, J | 1 |
| van der Wall, HEC | 1 |
| Feiss, GL | 1 |
| Niemeyer-van der Kolk, T | 1 |
| Burggraaf, J | 1 |
| Bouwstra, JA | 1 |
| Rissmann, R | 1 |
| van Doorn, MBA | 1 |
| Koga, H | 1 |
| Munechika, Y | 1 |
| Matsumoto, H | 1 |
| Nanjoh, Y | 1 |
| Harada, K | 1 |
| Makimura, K | 1 |
| Tsuboi, R | 1 |
| Garg, A | 1 |
| Singh, C | 1 |
| Pradhan, D | 1 |
| Ghosh, G | 1 |
| Rath, G | 1 |
| Massiot, P | 1 |
| Clavaud, C | 1 |
| Thomas, M | 1 |
| Ott, A | 1 |
| Guéniche, A | 1 |
| Panhard, S | 1 |
| Muller, B | 1 |
| Michelin, C | 1 |
| Kerob, D | 1 |
| Bouloc, A | 1 |
| Reygagne, P | 1 |
| Choi, FD | 1 |
| Juhasz, MLW | 1 |
| Atanaskova Mesinkovska, N | 1 |
| Diehl, C | 1 |
| Ferrari, A | 1 |
| Buechner, SA | 1 |
| Liu, J | 1 |
| Warshaw, EM | 1 |
| Okokon, EO | 1 |
| Verbeek, JH | 1 |
| Ruotsalainen, JH | 1 |
| Ojo, OA | 1 |
| Bakhoya, VN | 1 |
| Nenoff, P | 2 |
| Krüger, C | 1 |
| Mayser, P | 1 |
| Bumroongthai, K | 1 |
| Chetanachan, P | 1 |
| Niyomtham, W | 1 |
| Yurayart, C | 1 |
| Prapasarakul, N | 1 |
| Zani, MB | 1 |
| Soares, RC | 1 |
| Arruda, AC | 1 |
| de Arruda, LH | 1 |
| Wang, K | 1 |
| Chi, Z | 1 |
| Shu, C | 1 |
| Li, L | 1 |
| Wei, J | 1 |
| Tao, L | 1 |
| Ma, P | 1 |
| Ding, L | 1 |
| Gupta, AK | 3 |
| Versteeg, SG | 1 |
| Scheinfeld, N | 1 |
| Koc, E | 1 |
| Arca, E | 1 |
| Kose, O | 1 |
| Akar, A | 1 |
| Imafuku, S | 1 |
| Nakayama, J | 1 |
| Naldi, L | 1 |
| Rebora, A | 1 |
| Manríquez, JJ | 1 |
| Uribe, P | 1 |
| Poindexter, GB | 1 |
| Burkhart, CN | 1 |
| Morrell, DS | 1 |
| Ortonne, JP | 2 |
| Nikkels, AF | 1 |
| Reich, K | 1 |
| Ponce Olivera, RM | 1 |
| Lee, JH | 1 |
| Kerrouche, N | 1 |
| Sidou, F | 1 |
| Faergemann, J | 4 |
| Draelos, ZD | 2 |
| Feldman, SR | 2 |
| Butners, V | 1 |
| Alió Saenz, AB | 1 |
| Piérard, GE | 5 |
| Chosidow, O | 2 |
| Maurette, C | 1 |
| Dupuy, P | 1 |
| Piérard-Franchimont, C | 4 |
| Arrese, JE | 2 |
| Dreno, B | 2 |
| Revuz, J | 1 |
| Moyse, D | 2 |
| Usatine, RP | 1 |
| Reichrath, J | 1 |
| Kupfer-Bessaguet, I | 1 |
| Misery, L | 2 |
| Plantin, P | 2 |
| Bluhm, R | 1 |
| Barlow, JO | 1 |
| Fleischer, AB | 1 |
| Savage, HI | 1 |
| Edgington, B | 1 |
| Appel, J | 1 |
| Abdulla, FR | 1 |
| Brodell, RT | 1 |
| Gee, BC | 1 |
| Wannanukul, S | 1 |
| Chiabunkana, J | 1 |
| Kenneally, DC | 1 |
| Hodges, LT | 1 |
| Billhimer, W | 1 |
| Copas, M | 1 |
| Margraf, C | 1 |
| Choczaj-Kukuła, A | 1 |
| Kwaśniewska, J | 1 |
| Roques, C | 1 |
| Brousse, S | 1 |
| Panizzutti, C | 1 |
| Seckin, D | 1 |
| Gurbuz, O | 1 |
| Akin, O | 1 |
| Sheffield, RC | 1 |
| Crawford, P | 1 |
| Wright, ST | 1 |
| King, VJ | 1 |
| Blouin, E | 1 |
| Ratnavel, RC | 1 |
| Squire, RA | 2 |
| Boorman, GC | 1 |
| Borgers, M | 2 |
| Degreef, H | 2 |
| Swinyer, LJ | 1 |
| Decroix, J | 1 |
| Langner, A | 1 |
| Quiring, JN | 1 |
| Blockhuys, S | 1 |
| Elewski, BE | 1 |
| Abramovits, W | 1 |
| Kempers, S | 1 |
| Schlessinger, J | 1 |
| Rosen, T | 1 |
| Abraham, S | 1 |
| Rowell, R | 1 |
| Ford, GP | 1 |
| Farr, PM | 3 |
| Ive, FA | 3 |
| Shuster, S | 3 |
| Hannuksela, M | 1 |
| Broberg, A | 1 |
| Peter, RU | 2 |
| Richarz-Barthauer, U | 1 |
| Danby, FW | 1 |
| Maddin, WS | 1 |
| Margesson, LJ | 1 |
| Rosenthal, D | 1 |
| Dobrev, H | 1 |
| Zissova, L | 1 |
| Bengtsson, A | 1 |
| Holm, L | 1 |
| Bäck, O | 1 |
| Fransson, J | 1 |
| Scheynius, A | 1 |
| Hay, RJ | 1 |
| Graham-Brown, RA | 1 |
| Hernanz Hermosa, JM | 1 |
| Lázaro Ochaita, P | 1 |
| Pari, T | 1 |
| Pulimood, S | 1 |
| Jacob, M | 1 |
| George, S | 1 |
| Jeyaseelan, L | 1 |
| Thomas, K | 1 |
| Seidenbaum, M | 1 |
| Bulmer, AC | 1 |
| Bulmer, GS | 1 |
| Reinl, P | 1 |
| Haustein, UF | 1 |
| De Doncker, P | 1 |
| Goode, K | 1 |
| Lacour, JP | 1 |
| Vitetta, A | 1 |
| Le Fichoux, Y | 1 |
| Verschueren, GL | 1 |
| Bruynzeel, DP | 1 |
| Van Cutsem, J | 2 |
| Rurangirwa, A | 1 |
| Hoppenbrouwers, ML | 1 |
| Schrooten, P | 2 |
| Korting, HC | 1 |
| Webster, G | 1 |
| Hill, MK | 2 |
| Goodfield, JD | 1 |
| Rodgers, FG | 2 |
| Crowley, JL | 2 |
| Saihan, EM | 2 |
| Nelson, ME | 1 |
| Midgley, G | 1 |
| Blatchford, NR | 1 |
| Van Gerven, F | 1 |
| Fransen, J | 1 |
| Janssen, PA | 1 |
| Goodfield, MJ | 1 |
| Taieb, A | 1 |
| Legrain, V | 1 |
| Palmier, C | 1 |
| Lejean, S | 1 |
| Six, M | 1 |
| Maleville, J | 1 |
| Coldiron, BM | 1 |
| Bergstresser, PR | 1 |
| Katsambas, A | 2 |
| Antoniou, C | 2 |
| Frangouli, E | 1 |
| Avgerinou, G | 1 |
| Michailidis, D | 1 |
| Stratigos, J | 1 |
| Sudan, BJ | 1 |
| Skinner, RB | 2 |
| Noah, PW | 2 |
| Zanolli, MD | 2 |
| Rosenberg, EW | 2 |
| Carr, MM | 1 |
| Pryce, DM | 1 |
| Green, CA | 1 |
| Wishner, AJ | 1 |
| Teplitz, ED | 1 |
| Goodman, DS | 1 |
| Buxton, PK | 1 |
| Baran, R | 1 |
| Satriano, RA | 1 |
| Florio, M | 1 |
| Grimaldi Filioli, F | 1 |
| Gregori, S | 1 |
| Grosshans, E | 1 |
| Bressieux, A | 1 |
| De Pedrini, P | 1 |
| Rapisarda, R | 1 |
| Spanò, G | 1 |
| Stratigos, JD | 1 |
| Böhler, K | 1 |
| Fritsch, P | 1 |
| Schmölz, A | 1 |
| Michaelidis, D | 1 |
| De Beule, K | 1 |
| Taylor, RM | 1 |
| West, S | 1 |
| Guin, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Clobetasol Propionate Shampoo 0.05% Used in Association With an Antifungal Shampoo in the Treatment of Moderate to Severe Scalp Seborrheic Dermatitis[NCT00862654] | Phase 3 | 326 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| A PHASE 4, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2% IN THE TREATMENT OF SEBORRHEIC DERMATITIS[NCT00703846] | Phase 4 | 498 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Total Severity Score (TSS) is sum of erythema, scaling and pruritus severity scores of the lesions evaluated each on a 4-point scale from 0 = None to 3 = Severe by the investigator. So minimum TSS can be 0 and maximum 9. (NCT00862654)
Timeframe: baseline and week 4
| Intervention | Percent change (Median) |
|---|---|
| C Propionate 4/Week + Ketoconazole 2/Week | -71.4 |
| C Propionate 2/Week + Ketoconazole 2/Week | -66.7 |
| C Propionate 2/Week | -66.7 |
| Ketakonazol 2/Week | -57.1 |
Skindex-29 is a 3-component (symptomatic, emotional, and functional) self-administered questionnaire (comprised of 30 questions) used to comprehensively measure the complex effects of skin diseases on a participant's quality of life. For the emotional component, participants were asked to answer 10 questions based on a 5-point scale concerning their feelings over the past 4 weeks about the skin condition that has bothered them the most: 1, never; 2, rarely; 3, sometimes; 4, often; 5, all the time. The Emotional Score is the sum of the 10 question scores; total score ranges from 10 to 50. (NCT00703846)
Timeframe: Baseline and Week 52 (or Early Termination)
| Intervention | units on a scale (Mean) |
|---|---|
| Extina (Ketoconazole) 2% | -5 |
Skindex-29 is a 3-component (symptomatic, emotional, and functional) self-administered questionnaire (comprised of 30 questions) used to comprehensively measure the complex effects of skin diseases on a participant's quality of life. For the functional component, participants were asked to answer 15 questions based on a 5-point scale concerning their feelings over the past 4 weeks about the skin condition that has bothered them the most: 1, never; 2, rarely; 3, sometimes; 4, often; 5, all the time. The Functional Score is the sum of the 12 question scores; total score ranges from 15 to 75. (NCT00703846)
Timeframe: Baseline and Week 52 (or Early Termination)
| Intervention | units on a scale (Mean) |
|---|---|
| Extina (Ketoconazole) 2% | -4 |
Skindex-29 is a 3-component (symptomatic, emotional, and functional) self-administered questionnaire (comprised of 30 questions) used to comprehensively measure the complex effects of skin diseases on a participant's quality of life. Participants were asked to answer questions based on a 5-point scale concerning their feelings over the past 4 weeks about the skin condition that has bothered them the most: 1, never; 2, rarely; 3, sometimes; 4, often; 5, all the time. The Global Score is the sum of the 30 question scores; total score ranges from 30 to 150. (NCT00703846)
Timeframe: Baseline and Week 52 (or Early Termination)
| Intervention | units on a scale (Mean) |
|---|---|
| Extina (Ketoconazole) 2% | -11 |
Skindex-29 is a 3-component (symptomatic, emotional, and functional) self-administered questionnaire (comprised of 30 questions) used to comprehensively measure the complex effects of skin diseases on a participant's quality of life. For the symptomatic component, participants were asked to answer 7 questions based on a 5-point scale concerning their feelings over the past 4 weeks about the skin condition that has bothered them the most: 1, never; 2, rarely; 3, sometimes; 4, often; 5, all the time. The Symptomatic Score is the sum of the 7 question scores; total score ranges from 7 to 35. (NCT00703846)
Timeframe: Baseline and Week 52 (or Early Termination)
| Intervention | units on a scale (Mean) |
|---|---|
| Extina (Ketoconazole) 2% | -3 |
The median number of flare days for all participants was calculated based on data self-reported in diaries that participants kept during the study. The median number of flares for all participants was calculated based on data self-reported in diaries that participants kept during the study. A flare day is defined as a day on which flare signs and symptoms for seborrheic dermatitis (erythema, scaling, and pruritus of the target area) occurred. (NCT00703846)
Timeframe: From baseline through 52 weeks
| Intervention | flare days (Median) |
|---|---|
| Extina (Ketoconazole) 2% | 109 |
The median number of flares for all participants was calculated based on data self-reported in diaries that participants kept during the study. A flare is defined as a clinical diagnosis and presentation of seborrheic dermatitis that shows as an erythematous, thin, scaly patch with a greasy sandpaper texture that varies depending on disease severity. Flares are commonly seen on the scalp, nasal folds, eyebrows, glabella, upper eyelids, retroauricular/external ear canal, and midchest areas. (NCT00703846)
Timeframe: From baseline through 52 weeks
| Intervention | flares (Median) |
|---|---|
| Extina (Ketoconazole) 2% | 7 |
"An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, which does not necessarily have a causal relationship with the treatment. For a list of all adverse events occurring at or above a frequency threshold of 5% during the course of the study, see the table entitled Other (Non-Serious) Adverse Events." (NCT00703846)
Timeframe: From baseline through 52 weeks
| Intervention | participants (Number) |
|---|---|
| Extina (Ketoconazole) 2% | 282 |
"This seborrhoeic dermatitis-specific ISGA scale (range=0-4) is used to assess skin condition severity without considering changes over time (static). 0=clear, except for minor residual discoloration; 1-4=majority of lesions have average scaling/erythema scores of 1-4, respectively. 1=almost clear, occasional fine scale, faint erythema/barely perceptible plaque thickness; 2= mild, fine scale with light coloration/mild plaque elevation; 3=moderate, coarse scale with moderate red coloration/moderate plaque thickness; 4=severe, thick tenacious scale with deep coloration/severe plaque thickness." (NCT00703846)
Timeframe: Baseline and Weeks 4, 8, 16, 26, 39, and 52 (or early termination)
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 4, n=451 | Week 8, n=436 | Week 16, n=405 | Week 26, n=381 | Week 39, n=370 | Week 52 (or Early Termination), n=420 | |
| Extina (Ketoconazole) 2% | -1 | -2 | -2 | -2 | -2 | -2 |
Mean change from baseline was calculated as the Week 4, 8, 16, 26, 39, and 52 (or early termination) value minus the baseline value. The grading scale for erythema ranges from 0 to 4; 0=Normal skin without erythema; may have residual hyper/hypopigmentation; 1=Faint erythema; may have residual hyper/hypopigmentation; 2=Light red erythema; may have residual hyper/hypopigmentation; 3=Moderate red coloration; 4=Dusky to deep red coloration. Erythema was defined as redness of the skin caused by increased blood circulation in the capillaries found in the deeper layers of the skin. (NCT00703846)
Timeframe: Baseline and Weeks 4, 8, 16, 26, 39, and 52 (or early termination)
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 4, n=451 | Week 8, n=436 | Week 16, n=405 | Week 26, n=381 | Week 39, n=370 | Week 52 (or Early Termination), n=420 | |
| Extina (Ketoconazole) 2% | -2 | -2 | -2 | -2 | -2 | -2 |
Mean change from baseline was calculated as the Week 4, 8, 16, 26, 39, and 52 (or Early Termination) value minus the baseline value. The grading scale for pruritis ranges from 0 to 4; 0=No itching; 1=Minimal: rarely aware of itching; 2=Mild: only aware of itching at times; only present when relaxing; not present when focused on other activities; 3=Moderate: often aware of itching; annoying; sometimes disturbs sleep and daytime activities; 4=Severe: constant itching; distressing; frequent sleep disturbance; interferes with activities. Pruritus is defined as an itching/scratching sensation. (NCT00703846)
Timeframe: Baseline and Weeks 4, 8, 16, 26, 39, and 52 (or early termination)
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 4, n=451 | Week 8, n=436 | Week 16, n=405 | Week 26, n=381 | Week 39, n=370 | Week 52 (or Early Termination), n=420 | |
| Extina (Ketoconazole) 2% | -2 | -2 | -2 | -2 | -2 | -2 |
Mean change from baseline in skin assessments for scaling was calculated as the Week 4, 8, 16, 26, 39, and 52 (or Early Termination) value minus the baseline value. The grading scale for scaling ranges from 0 to 4; 0=Normal skin with rare fine scale; 1=Minimal: occasional fine scales over less than 10% of the lesions; 2=Mild: fine scales predominate; 3=Moderate: coarse scales predominate; 4=Severe: thick tenacious scales predominate. Scaling of skin is the loss of the outer layer of the epidermis in large, scale-like flakes. (NCT00703846)
Timeframe: Baseline and Weeks 4, 8, 16, 26, 39, and 52 (or early termination)
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 4, n=451 | Week 8, n=436 | Week 16, n=405 | Week 26, n=381 | Week 39, n=370 | Week 52 (or Early Termination), n=420 | |
| Extina (Ketoconazole) 2% | -2 | -2 | -2 | -2 | -2 | -2 |
24 reviews available for ketoconazole and Dermatitis Seborrheica
| Article | Year |
|---|---|
Topical ketoconazole: a systematic review of current dermatological applications and future developments.
Topics: Administration, Topical; Alopecia; Antifungal Agents; Dermatitis, Seborrheic; Humans; Ketoconazole; | 2019 |
Topical antifungals for seborrhoeic dermatitis.
Topics: Adolescent; Adult; Antifungal Agents; Ciclopirox; Clotrimazole; Dermatitis, Seborrheic; Facial Derma | 2015 |
[Cutaneous Malassezia infections and Malassezia associated dermatoses: An update].
Topics: Antifungal Agents; Dermatitis, Atopic; Dermatitis, Seborrheic; Itraconazole; Ketoconazole; Malassezi | 2015 |
Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Antifungal Agents; Calcineurin Inhibitors; Cicl | 2017 |
Ketoconazole: a review of a workhorse antifungal molecule with a focus on new foam and gel formulations.
Topics: Antifungal Agents; Chemistry, Pharmaceutical; Dermatitis, Seborrheic; Gels; Humans; Ketoconazole | 2008 |
Clinical practice. Seborrheic dermatitis.
Topics: Administration, Topical; Adrenal Cortex Hormones; Antifungal Agents; Dermatitis, Seborrheic; Humans; | 2009 |
Seborrhoeic dermatitis.
Topics: Administration, Oral; Administration, Topical; Dermatitis, Seborrheic; Face; Humans; Ketoconazole; L | 2007 |
Therapies for pediatric seborrheic dermatitis.
Topics: Administration, Cutaneous; Adolescent; Adult; Antifungal Agents; Child; Dermatitis, Seborrheic; Drug | 2009 |
Ketoconazole foam--connetics: connetics ketoconazole foam.
Topics: Administration, Cutaneous; Antifungal Agents; Clinical Trials as Topic; Dermatitis, Seborrheic; Dosa | 2003 |
Seborrhoeic dermatitis.
Topics: Dermatitis, Seborrheic; Humans; Imidazoles; Ketoconazole; Scalp Dermatoses; Selenium Compounds | 2004 |
[Current possibilities of using antimyocotic drugs in the treatment of various skin disorders].
Topics: Animals; Antifungal Agents; Dermatitis, Atopic; Dermatitis, Seborrheic; Dermatomycoses; Female; Huma | 2004 |
Clinical inquiries. What's the best treatment for cradle cap?
Topics: Administration, Topical; Dermatitis, Seborrheic; Emollients; Evidence-Based Medicine; Family Practic | 2007 |
A new ketoconazole topical gel formulation in seborrhoeic dermatitis: an updated review of the mechanism.
Topics: Administration, Topical; Antifungal Agents; Dermatitis, Seborrheic; Gels; Humans; Ketoconazole | 2007 |
Ketoconazole gel 2% in the treatment of moderate to severe seborrheic dermatitis.
Topics: Administration, Topical; Antifungal Agents; Clinical Trials, Phase III as Topic; Dermatitis, Seborrh | 2007 |
The role of ketoconazole in seborrheic dermatitis.
Topics: Administration, Topical; Antifungal Agents; Dermatitis, Seborrheic; Dermatomycoses; Gels; Humans; Ke | 2007 |
Dandruff and seborrhoeic dermatitis: causes and management.
Topics: Antifungal Agents; Dermatitis, Seborrheic; Humans; Ketoconazole; Malassezia; Mycoses; Scalp Dermatos | 1997 |
[Superficial mycoses in immunosuppressed patients].
Topics: Adult; Antifungal Agents; Candidiasis, Cutaneous; Candidiasis, Oral; Candidiasis, Vulvovaginal; Chil | 1995 |
[Seborrheic dermatitis].
Topics: Administration, Topical; Anti-Inflammatory Agents; Antifungal Agents; Dermatitis, Seborrheic; Emolli | 1997 |
[Etiology, pathogenesis and treatment of seborrheic dermatitis].
Topics: Dermatitis, Seborrheic; Humans; Ketoconazole; Lithium | 2000 |
[The yeast fungus Malassezia: pathogen, pathogenesis and therapy].
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Child; Dermatitis, Atop | 2001 |
An overview of experience with ketoconazole shampoo.
Topics: Clinical Trials as Topic; Dermatitis, Seborrheic; Glucocorticoids; Humans; Ketoconazole; Malassezia; | 1991 |
Seborrheic dermatitis.
Topics: Antifungal Agents; Central Nervous System Diseases; Dermatitis; Dermatitis, Seborrheic; Humans; Keto | 1991 |
ABC of dermatology. Rashes with epidermal changes--I.
Topics: Adult; Dermatitis, Seborrheic; Erythema; Female; Humans; Infant; Ketoconazole; Lichen Planus; Male; | 1987 |
[Seborrheic eczema (pityriasporosis)].
Topics: Adult; Coal Tar; Dermatitis, Seborrheic; Eczema; Facial Dermatoses; Humans; Ketoconazole; Malassezia | 1988 |
35 trials available for ketoconazole and Dermatitis Seborrheica
| Article | Year |
|---|---|
Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial.
Topics: Antifungal Agents; Antimicrobial Peptides; Dermatitis, Seborrheic; Humans; Ketoconazole; Malassezia; | 2023 |
Efficacy of topical 4% Quassia amara gel in facial seborrheic dermatitis:a randomized, double-blind, comparative study.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Ciclopirox | 2013 |
Multicenter, double-blind, parallel group study investigating the non-inferiority of efficacy and safety of a 2% miconazole nitrate shampoo in comparison with a 2% ketoconazole shampoo in the treatment of seborrhoeic dermatitis of the scalp.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Dandruff; Dermatitis, Seborrheic; Double-Blind M | 2014 |
A highly sensitive LC-MS/MS method for determination of ketoconazole in human plasma: Application to a clinical study of the exposure to ketoconazole in patients after topical administration.
Topics: Administration, Topical; Adult; Chromatography, High Pressure Liquid; Dermatitis, Seborrheic; Drug S | 2016 |
An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis.
Topics: Adult; Chi-Square Distribution; Dermatitis, Seborrheic; Dose-Response Relationship, Drug; Drug Admin | 2009 |
Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0·05% combined with ketoconazole shampoo 2%: a randomized, controlled study.
Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Antifungal Agents; Clobetasol; Dermatiti | 2011 |
Long-term safety of ketoconazole foam, 2% in the treatment of seborrheic dermatitis: results of a phase IV, open-label study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antifungal Agents; Child; Chronic Disease; | 2013 |
Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrheic dermatitis.
Topics: Adult; Ciclopirox; Dermatitis, Seborrheic; Dermatologic Agents; Double-Blind Method; Facial Dermatos | 2003 |
Lithium gluconate 8% vs ketoconazole 2% in the treatment of seborrhoeic dermatitis: a multicentre, randomized study.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Dermatitis, Seborrheic; Dermatologic Agents; Female; Glu | 2003 |
A comparison of hair quality and cosmetic acceptance following the use of two anti-dandruff shampoos.
Topics: Adult; Antifungal Agents; Cross-Over Studies; Dermatitis, Seborrheic; Double-Blind Method; Erythema; | 2005 |
Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: a randomized, double-blind study.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Chi-Squar | 2007 |
Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Child; Ciclopirox; Dermatitis, Seborrheic; Double-Blind | 2007 |
A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Child; Derma | 2007 |
The response of seborrhoeic dermatitis to ketoconazole.
Topics: Adolescent; Adult; Clinical Trials as Topic; Dermatitis, Seborrheic; Double-Blind Method; Female; Hu | 1984 |
Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial.
Topics: Adult; Dermatitis, Seborrheic; Double-Blind Method; Female; Hair Preparations; Humans; Ketoconazole; | 1995 |
A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Dermatitis, Seborrheic; Double-Blind Method; Femal | 1993 |
Effect of ketoconazole 2% shampoo on scalp sebum level in patients with seborrhoeic dermatitis.
Topics: Administration, Topical; Adolescent; Adult; Dermatitis, Seborrheic; Female; Hair Preparations; Human | 1997 |
[Management of seborrhoic dermatitis].
Topics: Azoles; Dermatitis, Seborrheic; Diagnosis, Differential; Enzyme Inhibitors; Humans; Ketoconazole; Pl | 1994 |
Randomised double blind controlled trial of 2% ketoconazole cream versus 0.05% clobetasol 17-butyrate cream in seborrhoeic dermatitis.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Antifungal Agents; Clobetasol; Dermatitis, | 1998 |
Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrhoeic dermatitis: clinical, squamometric and mycological assessments.
Topics: Adult; Aged; Dermatitis, Seborrheic; Dermatomycoses; Double-Blind Method; Female; Hair Preparations; | 2001 |
A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Antifungal Agents; Child; Ciclopirox; Dermatitis | 2002 |
A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis.
Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents; Antifungal Agents; Dermatitis, Seborrhei | 2002 |
Comparative study of ketoconazole 2% foaming gel and betamethasone dipropionate 0.05% lotion in the treatment of seborrhoeic dermatitis in adults.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Dermatiti | 1992 |
Ketoconazole 2% emulsion in the treatment of seborrheic dermatitis.
Topics: Dermatitis, Seborrheic; Double-Blind Method; Emulsions; Female; Humans; Ketoconazole; Malassezia; Ma | 1991 |
[Treatment of seborrhoeic eczema with ketoconazole in comparison with an active agent-free cream].
Topics: Administration, Topical; Adult; Dermatitis, Seborrheic; Double-Blind Method; Female; Humans; Ketocon | 1991 |
Treatment of seborrhoeic dermatitis of the scalp with ketoconazole shampoo. A double-blind study.
Topics: Adult; Dermatitis, Seborrheic; Double-Blind Method; Female; Humans; Ketoconazole; Malassezia; Male; | 1990 |
Skin surface electron microscopy in Pityrosporum folliculitis. The role of follicular occlusion in disease and the response to oral ketoconazole.
Topics: Administration, Oral; Dermatitis, Seborrheic; Dermatomycoses; Double-Blind Method; Eczema; Female; F | 1990 |
Ketoconazole in the treatment of blepharitis.
Topics: Adult; Aged; Aged, 80 and over; Blepharitis; Dermatitis, Seborrheic; Double-Blind Method; Eyelid Dis | 1990 |
Skin surface electron microscopy in Pityrosporum folliculitis. The role of follicular occlusion in disease and the response to oral ketoconazole.
Topics: Administration, Oral; Dermatitis, Seborrheic; Dermatomycoses; Double-Blind Method; Eczema; Female; F | 1990 |
A double-blind trial of treatment of seborrhoeic dermatitis with 2% ketoconazole cream compared with 1% hydrocortisone cream.
Topics: Administration, Topical; Anti-Inflammatory Agents; Dermatitis, Seborrheic; Double-Blind Method; Huma | 1989 |
Treatment of seborrhoeic dermatitis with ketoconazole: I. Response of seborrhoeic dermatitis of the scalp to topical ketoconazole.
Topics: Administration, Topical; Adult; Aged; Clinical Trials as Topic; Dermatitis, Seborrheic; Double-Blind | 1987 |
Treatment of seborrhoeic dermatitis with ketoconazole: II. Response of seborrhoeic dermatitis of the face, scalp and trunk to topical ketoconazole.
Topics: Administration, Topical; Adolescent; Adult; Aged; Clinical Trials as Topic; Dermatitis, Seborrheic; | 1987 |
[Seborrheic dermatitis: use of ketoconazole cream and shampoo. Double-blind study versus placebo].
Topics: Adolescent; Adult; Dermatitis, Seborrheic; Double-Blind Method; Drug Evaluation; Female; Hair Prepar | 1987 |
Ketoconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis. A double-blind comparative study.
Topics: Administration, Cutaneous; Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agent | 1988 |
Double-blind treatment of seborrheic dermatitis with 2% ketoconazole cream.
Topics: Administration, Topical; Clinical Trials as Topic; Dermatitis, Seborrheic; Double-Blind Method; Huma | 1985 |
36 other studies available for ketoconazole and Dermatitis Seborrheica
| Article | Year |
|---|---|
Ketoconazole beyond antifungal activity: Bioinformatics-based hypothesis on lipid metabolism in dandruff and seborrheic dermatitis.
Topics: Antifungal Agents; Biotin; Computational Biology; Dandruff; Dermatitis, Seborrheic; Humans; Ketocona | 2022 |
Ketoconazole 2% cream alters the skin fungal microbiome in seborrhoeic dermatitis: a cohort study.
Topics: Cohort Studies; Dermatitis, Seborrheic; Humans; Ketoconazole; Malassezia; Mycobiome; Prospective Stu | 2022 |
Guinea pig seborrheic dermatitis model of Malassezia restricta and the utility of luliconazole.
Topics: Administration, Topical; Animals; Antifungal Agents; Dermatitis, Seborrheic; Disease Models, Animal; | 2020 |
Topical application of nanoparticles integrated supramolecular hydrogels for the potential treatment of seborrhoeic dermatitis.
Topics: Administration, Topical; Animals; Antifungal Agents; Dermatitis, Seborrheic; Goats; HeLa Cells; Huma | 2020 |
Continuous clinical improvement of mild-to-moderate seborrheic dermatitis and rebalancing of the scalp microbiome using a selenium disulfide-based shampoo after an initial treatment with ketoconazole.
Topics: Dandruff; Dermatitis, Seborrheic; Hair Preparations; Humans; Ketoconazole; Malassezia; Microbiota; S | 2022 |
Allergic contact dermatitis from ketoconazole.
Topics: Aged; Antifungal Agents; Dermatitis, Allergic Contact; Dermatitis, Seborrheic; Diagnosis, Differenti | 2014 |
Biofilm production and antifungal susceptibility of co-cultured Malassezia pachydermatis and Candida parapsilosis isolated from canine seborrheic dermatitis.
Topics: Animals; Antifungal Agents; Biofilms; Candida; Dermatitis, Seborrheic; Dog Diseases; Dogs; Itraconaz | 2016 |
Ketoconazole does not decrease fungal amount in patients with seborrhoeic dermatitis.
Topics: Administration, Topical; Antifungal Agents; Back; Case-Control Studies; Dermatitis, Seborrheic; Derm | 2016 |
Contact allergy to ketoconazole cross-sensitive to miconazole.
Topics: Aged; Antifungal Agents; Cross Reactions; Dermatitis, Contact; Dermatitis, Seborrheic; Drug Eruption | 2009 |
Seborrheic dermatitis today, gone tomorrow? The link between the biocene and treatment.
Topics: Antifungal Agents; Ciclopirox; Clinical Trials as Topic; Dermatitis, Seborrheic; Dermatomycoses; Hum | 2003 |
[How to manage seborrheic dermatitis].
Topics: Antifungal Agents; Dermatitis, Seborrheic; Humans; Itraconazole; Ketoconazole; Malassezia | 2003 |
A red rash on the face.
Topics: Anti-Inflammatory Agents; Antifungal Agents; Dermatitis, Seborrheic; Humans; Hydrocortisone; Ketocon | 2003 |
Antimycotics: why are they effective in the treatment of seborrheic dermatitis?
Topics: Antifungal Agents; Clinical Trials as Topic; Dermatitis, Seborrheic; Female; Humans; Ketoconazole; M | 2004 |
[Treatment for seborrheic dermatitis].
Topics: Administration, Topical; Antifungal Agents; Dermatitis, Seborrheic; Humans; Ketoconazole | 2004 |
Prescribing practices for seborrheic dermatitis vary with the physician's specialty: implications for clinical practice.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Dermatitis, Seborrheic; Dermatology; Drug Uti | 2004 |
Transient band-like keratopathy after treatment for seborrheic dermatitis.
Topics: Administration, Topical; Adult; Antifungal Agents; Corneal Diseases; Dermatitis, Seborrheic; Epithel | 2005 |
Seborrheic dermatitis. The link between facial rash and neurologic disease.
Topics: Anti-Infective Agents, Local; Antifungal Agents; Dermatitis, Seborrheic; Humans; Ketoconazole; Male; | 2005 |
Comparative study of 2% ketoconazole cream and 1% hydrocortisone cream in the treatment of infantile seborrheic dermatitis.
Topics: Adolescent; Anti-Inflammatory Agents; Antifungal Agents; Child; Child, Preschool; Dermatitis, Seborr | 2004 |
In vitro antifungal efficacy of ciclopirox olamine alone and associated with zinc pyrithione compared to ketoconazole against Malassezia globosa and Malassezia restricta reference strains.
Topics: Antifungal Agents; Ciclopirox; Dermatitis, Seborrheic; Drug Therapy, Combination; Hair Preparations; | 2006 |
[Lithium gluconate 8% in the treatment of seborrheic dermatitis].
Topics: Administration, Topical; Dermatitis, Seborrheic; Gluconates; Humans; Inflammation; Ketoconazole; Lit | 2007 |
Treatment of seborrhoeic dermatitis with topical ketoconazole.
Topics: Administration, Topical; Dermatitis, Seborrheic; Humans; Ketoconazole; Male | 1984 |
[Treatment of seborrhoeic dermatitis].
Topics: Administration, Topical; Anti-Inflammatory Agents; Dermatitis, Seborrheic; Dermatologic Agents; Gluc | 1994 |
Pityrosporum ovale in healthy children, infantile seborrhoeic dermatitis and atopic dermatitis.
Topics: Adolescent; Adult; Antibodies, Fungal; Asthma; Candida albicans; Case-Control Studies; Child; Child, | 1995 |
Ketoconazole shampoo for dandruff.
Topics: Dermatitis, Seborrheic; Hair Preparations; Humans; Ketoconazole; Malassezia; Scalp Dermatoses | 1994 |
Elevated serum levels of soluble CD30 in patients with atopic dermatitis (AD).
Topics: Adolescent; Adult; Aged; Antifungal Agents; Blood Proteins; Dermatitis, Atopic; Dermatitis, Seborrhe | 1997 |
The antifungal action of dandruff shampoos.
Topics: Antifungal Agents; Colony Count, Microbial; Dermatitis, Seborrheic; Hair Preparations; Humans; Ketoc | 1999 |
Hypersensitivity to ketoconazole.
Topics: Adult; Dermatitis, Seborrheic; Drug Eruptions; Humans; Ketoconazole; Male; Patch Tests | 1992 |
The in vitro antifungal activity of ketoconazole, zinc pyrithione, and selenium sulfide against Pityrosporum and their efficacy as a shampoo in the treatment of experimental pityrosporosis in guinea pigs.
Topics: Animals; Antifungal Agents; Dermatitis, Seborrheic; Dermatomycoses; Disease Models, Animal; Guinea P | 1990 |
Topical ketoconazole for infantile seborrhoeic dermatitis.
Topics: Administration, Cutaneous; Dermatitis, Seborrheic; Female; Humans; Infant; Ketoconazole; Male | 1990 |
Prevalence and clinical spectrum of skin disease in patients infected with human immunodeficiency virus.
Topics: Adult; Candidiasis; Dermatitis, Seborrheic; HIV Seropositivity; Homosexuality; Humans; Injections, I | 1989 |
Ketoconazole, leukotrienes, Paf-acether and nicotine as a hapten: the possible aetiology of seborrhoeic dermatitis.
Topics: Acquired Immunodeficiency Syndrome; Antipsychotic Agents; Dermatitis, Seborrheic; Haptens; Humans; K | 1987 |
The pathogenic role of microbes in seborrheic dermatitis.
Topics: Acquired Immunodeficiency Syndrome; Dermatitis, Seborrheic; Dermatomycoses; Humans; Ketoconazole; Ma | 1986 |
Pityrosporum, ketoconazole, and seborrheic dermatitis.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Dermatitis, Seborrheic; Humans; Ketoconazo | 1987 |
[Clinical contribution to the treatment of dermatitis seborrheica of the face with ketoconazole cream].
Topics: Administration, Topical; Dermatitis, Seborrheic; Drug Administration Schedule; Facial Dermatoses; Fe | 1987 |
The effect of ketoconazole on sebum secretion in patients suffering from acne and seborrhoea.
Topics: Acne Vulgaris; Adult; Dermatitis, Seborrheic; Female; Humans; Ketoconazole; Male; Sebum | 1988 |
Treatment of sebopsoriasis with itraconazole.
Topics: Adult; Aged; Antifungal Agents; Dermatitis, Seborrheic; Female; Humans; Itraconazole; Ketoconazole; | 1985 |